ScholarIQanswers from OpenAlex & ORCID
Pedro Herranz
ResearcherPublications, citations & collaboration network
Pedro Herranz is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Pedro Herranz have?
ScholarIQindexed works
Pedro Herranz has 231 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Pedro Herranz have?
ScholarIQcitation count
Pedro Herranz has 5,251 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Pedro Herranz?
ScholarIQh-index
Pedro Herranz has an h-index of 34 in OpenAlex.
What is the i10-index of Pedro Herranz?
ScholarIQi10-index
Pedro Herranz has an i10-index of 94 in OpenAlex.
What is the ORCID of Pedro Herranz?
ScholarIQorcid
The ORCID for Pedro Herranz is on the source record.
What is the OpenAlex record for Pedro Herranz?
ScholarIQopenalex
The OpenAlex for Pedro Herranz is on the source record.
What are the most-cited papers on Pedro Herranz?
ScholarIQmost cited works
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt, Marjolein de Bruin‐Weller, Melinda Gooderham, Jennifer Clay Cather, Jamie Weisman, David M. Pariser, Eric L. Simpson, Kim Papp, Hyuck-Ki Hong, Diana Rubel, Peter Foley, Errol P. Prens, C.E.M. Griffiths, Takafumi Etoh, Pedro Herranz, Ramón M. Pujol, Jacek C. Szepietowski, Karel Ettler, Lajos Kemény, Xiaoping Zhu, Bolanle Akinlade, Thomas Hultsch, Vera Mastey, Abhijit Gadkari, Laurent Eckert, Nikhil Amin, Neil M.H. Graham, Gianluca Pirozzi, Neil Stahl, George D. Yancopoulos, Brad Shumel
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky, Margitta Worm, Charles Lynde, J.‐P. Lacour, Lynda Spelman, Norito Katoh, Hidehisa Saeki, Yves Poulin, Aleksandra Lesiak, Leon Kircik, S.H. Cho, Pedro Herranz, Michael J. Cork, Ketty Peris, Louise Abildgaard Steffensen, B K Bang, Alexandra Kuznetsova, T.N. Jensen, Marie Louise Østerdal, Eric L. Simpson, the ECZTRA 1 and ECZTRA 2 study investigators
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches
Carlos González‐Herrada, Sara Rodríguez‐Martín, Lucía Cachafeiro, Victoria Lerma, Olga González, José A. Lorente, Antonio Rodríguez, J. González-Ramos, Gastón Roustán, Elena Ramı́rez, Teresa Bellón, Francisco J. de Abajo, Teresa Bellón, Rosario Cabañas, Lucía Cachafeiro, A. García de Lorenzo, J. González-Ramos, Olga Hernández, Pedro Herranz, Elena Ramı́rez, Elena Bravo, Yolanda Alonso, José Antonio Aramburu, Natalia Cámara, Olga González, Carlos González‐Herrada, Olga Laosa, José A. Lorente, Amelia Moscoso, Concepción Payares, Gastón Roustán, Francisco J. de Abajo, Alicia González Quesada, Victoria Lerma, Sara Rodríguez‐Martín
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting
R. Navarro, Eva Vilarrasa, Pedro Herranz, L. Puig, X. Bordas, J.M. Carrascosa, R. Taberner, Marta Ferrán, M. García‐Bustinduy, A. Romero-Maté, R Pedragosa, Amaro García‐Diez, E. Daudén
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings
A. Nuño‐González, Pilar Martín-Carrillo, K. Magaletsky, M.D. Martin Rios, Cristina Herranz Mañas, J. Artigas Almazan, Gonzalo García de Casasola Sánchez, Emma Castro, Andrea Arenas, Ander Mayor Ibarguren, Marta Feito Rodríguez, B. Lozano‐Masdemont, María Beato, Elena Bravo, Paloma Oliver, María Dolores Montero Vega, Pedro Herranz